High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population

Haematologica. 2020 Oct 1;105(10):e507. doi: 10.3324/haematol.2019.229260.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1
  • Antigens, CD34
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / therapy
  • Neoplastic Stem Cells
  • Receptors, G-Protein-Coupled
  • Recurrence

Substances

  • ADGRG1 protein, human
  • Antigens, CD34
  • Receptors, G-Protein-Coupled
  • ADP-ribosyl Cyclase 1

Grants and funding

Funding: this study was supported by the Verein zusammen gegen den Krebs e.V and the Deutsche Jose-Carreras-Stiftung (04R/2016 and PS15/05).